Article
The primary failed. The key secondary failed. But this biotech still believes it can win an FDA OK
Rating:
0.0
Views:
90
Likes:
1
Library:
1
Two years after the executive team at BrainStorm Cell Therapeutics decided to back off a controversial attempt to sell their stem cell therapy for ALS under the new 'Right to Try' legislation, the biotech is back with the top-line data from Phase III. And the data aren't good. Researchers say
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value